Urogen Pharma Ltd (URGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2022 | 06-2022 | 03-2022 | 12-2021 | 09-2021 | |
| Sales | 16,097 | 16,604 | 13,564 | 16,174 | 11,351 |
| Cost of Goods | 2,020 | 1,846 | 1,525 | 1,589 | 1,244 |
| Gross Profit | 14,077 | 14,758 | 12,039 | 14,585 | 10,107 |
| Operating Expenses | 32,184 | 34,319 | 34,521 | 35,089 | 33,791 |
| Operating Income | -18,087 | -18,715 | -21,957 | -19,915 | -23,440 |
| Interest Expense | 2,694 | 2,239 | 282 | 0 | 0 |
| Other Income | -4,341 | -5,705 | -5,828 | -7,400 | -6,771 |
| Pre-tax Income | -25,122 | -26,659 | -28,067 | -27,315 | -30,211 |
| Income Tax | 709 | 32 | 325 | 1,137 | N/A |
| Net Income Continuous | -25,831 | -26,691 | -28,392 | -28,452 | -30,211 |
| Net Income | $-25,831 | $-26,691 | $-28,392 | $-28,452 | $-30,211 |
| EPS Basic Total Ops | -1.13 | -1.18 | -1.25 | -1.27 | -1.35 |
| EPS Basic Continuous Ops | -1.13 | -1.18 | -1.25 | -1.27 | -1.35 |
| EPS Diluted Total Ops | -1.13 | -1.18 | -1.25 | -1.27 | -1.35 |
| EPS Diluted Continuous Ops | -1.13 | -1.18 | -1.25 | -1.27 | -1.35 |
| EBITDA(a) | $-18,110 | $-18,362 | $-21,692 | $-19,569 | $-23,061 |